Merck KGaA (FRA:MRK) has been assigned a €100.00 ($116.28) price objective by stock analysts at JPMorgan Chase & Co. in a report issued on Tuesday, May 7th, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 14.13% from the stock’s previous close.
A number of other brokerages also recently issued reports on MRK. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the stock a “buy” rating in a research note on Monday, April 8th. Barclays set a €82.00 ($95.35) price target on Merck KGaA and gave the stock a “sell” rating in a report on Monday, April 8th. Warburg Research set a €103.00 ($119.77) price target on Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, April 9th. UBS Group set a €108.00 ($125.58) price target on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, April 1st. Finally, DZ Bank restated a “neutral” rating on shares of Merck KGaA in a report on Tuesday, April 2nd. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and six have given a buy rating to the stock. Merck KGaA has an average rating of “Hold” and a consensus price target of €101.25 ($117.73).
Shares of FRA MRK traded down €2.06 ($2.40) during trading hours on Tuesday, reaching €87.62 ($101.88). The stock had a trading volume of 559,919 shares. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: Bollinger Bands
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.